Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

← Verified COAs & $/mg for this compound

Guide|20 CitationsHormonal & GHFemale-friendly

Sermorelin Research Dosing Reference

Also known as: GHRH (1-29), Geref, Nocturnal GH Secretagogue

Dose Range
0.3 mgResearch range
0Typical research window: 0.3 mg0.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Growth Hormone Deficiency Study): 0.3 mg, Daily.

Protocol at a Glance
How Often
Daily

Daily

A Typical Run
12 months

Research-reported range; the linked study used a different dose or units.

How It's Taken
Vial

Subcutaneous

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 0.3 mg12 units

All U-100: 100 units = 1 mL. 16 doses in the vial at the low end.

Track the doses you run

Save Sermorelin to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Sermorelin supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$36.00 net$72.00
10mg Lyophilized Vial
$3.60/mg$7.20/mg retail
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$70.00
10mg vial
$7.00/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$69.99
10mg vial
$7.00/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$75.00
10mg vial
$7.50/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$83.00
10mg vial
$8.30/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$43.00
5mg vial
$8.60/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$48.00
5mg vial
$9.60/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$49.00
5mg vial
$9.80/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-9002345 (99.31%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$60.00
5mg vial
$12.00/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Pituitary Growth Hormone Secretagogue (GHRH Analog / Ghrelin Receptor Agonist)
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Growth Hormone Secretagogue?

A compound that stimulates your pituitary gland to release more of its own growth hormone (GH). Unlike synthetic GH injection, secretagogues trigger natural pulsatile GH release. Examples: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin. MK-677 (Ibutamoren) is technically not a peptide but acts as an oral GH secretagogue.

Sermorelin is the same active compound as Geref (discontinued) (EMD Serono). Not FDA approved in the US.

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Sermorelin is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone. It stimulates the pituitary gland to produce and release growth hormone.

Mechanisms of Action

  • Binds to GHRH receptors in pituitary
  • Stimulates GH synthesis and secretion
  • Preserves normal feedback mechanisms
  • Does not suppress natural GH production

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Growth Hormone Deficiency Study
reported protocol
0.3 mgDaily12 monthsSubcutaneoushuman
Baseline & Mid-Cycle Biomarker Bloodwork Panel

GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (Sermorelin)

Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

Serum IGF-1 (LC/MS) + Z-Score

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.

Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).

Fasting Insulin & HOMA-IR

Day 0 + Wk 6–8

Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.

Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.

HbA1c & Fasting Plasma Glucose

Day 0 + Wk 6–8

Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.

Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.

hs-CRP, Prolactin & CMP

Day 0 + Wk 6–8

Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.

Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

20 Human

Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Journal of the American Academy of Orthopaedic Surgeons. Global research &amp; reviews
PubMed

Finally, both MIA-602 and MIA-690 enhanced radiosensitivity in primary human NSCLC cells. These findings highlight the potential of GHRH antagonists as radiosensitizers in NSCLC treatment.

Limitations: No placebo control reported.

2025|International journal of molecular sciences
PubMed

Nearly all requirements of the recent technical documents from the World Anti-Doping Agency (WADA) considering their minimum required performance levels (MRPL) are fulfilled, and the method was validated for its utilisation as initial testing procedure in doping controls. Finally, the approach was applied to authentic post-administration study urine samples (for insulins and gonadorelin) in order to provide proof of principle.

Limitations: No placebo control reported.

2024|Journal of mass spectrometry : JMS
PubMed

GHRP-4, GHRP-6 and Sermorelin (22-29) can be considered as in-house ISs as they were stable to enzyme and blood treatment and can be used for the quantification of peptides in biological samples. Peptides GHRP-6 and Sermorelin (22-29) were used to analyse a dimeric peptide (26 [F] LfcinB (20-30)2 ) in four different matrices to test these peptides as in-house IS.

Limitations: No placebo control reported.

2023|Biomedical chromatography : BMC
PubMed

An optimized C18 SPE was used for that purpose in order to provide low sample conductivity (<130&#xa0;&#xb5;S/cm) and preserve the efficiency of LVSS preconcentration. SEF of 640 was obtained with desalted urine spiked with sermorelin by comparison to the CZE (without preconcentration) method.

Limitations: No placebo control reported.

2023|Electrophoresis
PubMed

After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin. Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status.

Limitations: No placebo control reported.

2022|Annals of translational medicine
PubMed

Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 microg/kg bodyweight dose in conjunction with conventional tests. Limited data suggest that once daily subcutaneous sermorelin 30 microg/kg bodyweight is effective in promoting growth in some prepubertal children with idiopathic growth hormone deficiency.

Limitations: No placebo control reported.

2009|BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
PubMed

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (Clinical interventions in aging, 2008)

Limitations: No placebo control reported.

2008|Clinical interventions in aging
PubMed

The effect of PEG molecular weight, number of PEG chains bound and position of PEGylation site on GRF activity were investigated. Mono-PEGylated isomers with a PEG5000 polymer chain linked to Lys 12 or Lys 21 residues, showed high biological activity in vitro, which is similar to that of hGRF1-29, and a higher pharmacodynamic response as compared to unmodified GRF molecule.

Limitations: No placebo control reported. Review article — no new primary data.

2004|Advanced drug delivery reviews
PubMed

In conclusion, the use of GH secretagogues plus GHRH is an easy, reliable and accurate way of assessing GH secretion in cranially irradiated patients. Impairment of the GH releasable pool in the irradiated patients, with a maximal provocative test, reflects alterations in the hypothalamic-pituitary unit caused by radiotherapy.

Limitations: No placebo control reported.

2002|The Journal of clinical endocrinology and metabolism
PubMed

These findings indicate that GH is effective in accelerating growth in GH-deficient children who do not show or maintain a satisfactory response to treatment with GHRH. In addition, they suggest that the initial response to GH therapy used in this way can be predicted by means of provoc-ative testing.

Limitations: No placebo control reported.

2002|Endocrine
PubMed

Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group using 0.15 microg/kg (median peak Irradiated, 4. 5mU/l vs median Controls, 37.4mU/l; P<0.01) and 1.0 microg/kg (median peak Irradiated, 4.8mU/l vs median Controls, 15.2mU/l; P<0.

Limitations: No placebo control reported.

2000|European journal of endocrinology
PubMed

When the light turns blue. (Endocrinology, 1997)

Limitations: No placebo control reported. Review article — no new primary data.

1997|Endocrinology
PubMed

GHRH treatment may increase muscle strength, and it alters baseline relationships between muscle strength and muscle bioenergetics in a manner consistent with a reduced need for anaerobic metabolism during exercise. Thus, an optimized regimen of GHRH administration might attenuate some of the effects of aging on skeletal muscle function in older persons.

Limitations: No placebo control reported.

1997|Metabolism: clinical and experimental
PubMed

On the basis of these results we were able to separate our patients into two groups: a) responders to priming (n = 8), whose GH responses to pharmacological and acute GHRH tests were < 10 ng/ml, with a 12-hour sleep secretion < 3 ng/ml/min. Priming increased the plasma GH response to acute GHRH in all the children in this group (6.0 +/- 2.1 ng/ml to 18.0 +/- 5.4 ng/ml; p < 0.001); b) non-responders to priming (n = 8), whose GH responses to pharmacological and acute GHRH tests were also < 10 ng/ml, with 12-hour sleep secretion < 3 ng/ml/min, but in whom priming with GH did not increase the plasma GH response (5.5 +/- 2.8 ng/ml to 6.2 +/- 2.9 ng/ml; p = NS).(ABSTRACT TRUNCATED AT 250 WORDS).

Limitations: No placebo control reported.

1995|The Journal of pediatric endocrinology
PubMed

GH response to GHRH in HA men was exaggerated compared to SL men, and IGF-I concentration was also significantly increased in the presence of normal levels of IGFBP-3. No differences in TSH or PRL responses were found following TRH.

Limitations: No placebo control reported.

1995|Clinical endocrinology
PubMed

Mean (SD) height velocity (HV) increased from 4.8(0.9)cm/year pre-treatment to 7.2(1.6)cm/year after 12 months of therapy (P = 0.001). The children growing slowly (HV or = 25th centile) before treatment.

Limitations: No placebo control reported.

1994|Clinical endocrinology
PubMed

The GH response after repeated intranasal administration of GHRH(1-29)-NH2 was sustained; there was no suppression of GH secretion during the night following a day when GHRH(1-29)-NH2 had been given three times intranasally. Based on these findings and the obvious convenience of intranasal administration compared with injections, it would be justified to test intranasal therapy for treatment of short stature in children with GH deficiency caused by hypothalamic damage.

Limitations: No placebo control reported.

1993|Acta paediatrica (Oslo, Norway : 1992). Supplement
PubMed

We have shown this to be an effective therapy for some short, slowly growing children. Further studies are required to establish the optimal dosage regimen.

Limitations: No placebo control reported.

1990|Clinical endocrinology
PubMed

Early studies also indicate that long-term therapy with subcutaneous GHRH may increase growth velocity in some of these children. It is concluded that analogues of GHRH are useful in the investigation of the hypothalamopituitary axis, and may be important in the therapy of short stature.

Limitations: No placebo control reported. Review article — no new primary data.

1986|Clinics in endocrinology and metabolism
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Requires daily injections
  • •Effects diminish if not taken at bedtime
  • •May cause flushing or headache
  • •Not as potent as direct GH administration
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Sermorelin, baseline labs & clinician oversight.

Full Sermorelin $/mg comparison →
50% OFF AUTO-APPLIED$3.60/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Sermorelin: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $3.60/mg (10mg Lyophilized Vial, $36.00)
  2. 2. Elite Research USA — $7.00/mg (10mg vial, $70.00)
  3. 3. Swift Peptides — $7.00/mg (10mg vial, $69.99)

Where is the cheapest place to buy Sermorelin?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $3.60/mg (10mg Lyophilized Vial, $36.00 after the 50% new-customer partner-link discount). We compared 9 US suppliers with live, checked prices.

How much does Sermorelin cost per mg?

Verified US domestic prices currently range from $3.60/mg to $12.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Sermorelin approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.